Rotigotine extended release - Luye Pharma Group
Alternative Names: Jinyouping; LY-03003; LY-03009; Rotigotine extended release; Rotigotine Microspheres for InjectionLatest Information Update: 28 Aug 2025
At a glance
- Originator Luye Pharma Group
- Class Antiparkinsonians; Small molecules; Tetrahydronaphthalenes; Thiophenes
- Mechanism of Action Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Parkinson's disease
- Phase I Restless legs syndrome
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in Australia (IM, Controlled release)
- 28 Aug 2025 No recent reports of development identified for preclinical development in Restless legs syndrome in Europe (IM, Controlled release)
- 11 Nov 2024 Launched for Parkinson's disease in China (IM) before November 2024